Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma

Gabriel J. Starrett(Center for Cancer Research), Manisha Thakuria(Brigham and Women's Hospital), Tianqi Chen(Dana-Farber Cancer Institute), Christina Marcelus(Dana-Farber Cancer Institute), Jingwei Cheng(Brigham and Women's Hospital), Jason Nomburg(Dana-Farber Cancer Institute), Aaron R. Thorner(Dana-Farber Cancer Institute), Michael K. Slevin(Dana-Farber Cancer Institute), Winslow Powers(Dana-Farber Cancer Institute), Robert Burns(Dana-Farber Cancer Institute), Caitlin Perry(Dana-Farber Cancer Institute), Adriano Piris(Brigham and Women's Hospital), Frank C. Kuo(Brigham and Women's Hospital), Guilherme Rabinowits(Baptist Hospital of Miami), Anita Giobbie‐Hurder(Dana-Farber Cancer Institute), Laura E. MacConaill(Brigham and Women's Hospital), James A. DeCaprio(Brigham and Women's Hospital)
Genome Medicine
March 18, 2020
Cited by 117Open Access
Full Text

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin caused by either the integration of Merkel cell polyomavirus (MCPyV) and expression of viral T antigens or by ultraviolet-induced damage to the tumor genome from excessive sunlight exposure. An increasing number of deep sequencing studies of MCC have identified significant differences between the number and types of point mutations, copy number alterations, and structural variants between virus-positive and virus-negative tumors. However, it has been challenging to reliably distinguish between virus positive and UV damaged MCC. METHODS: In this study, we assembled a cohort of 71 MCC patients and performed deep sequencing with OncoPanel, a clinically implemented, next-generation sequencing assay targeting over 400 cancer-associated genes. To improve the accuracy and sensitivity for virus detection compared to traditional PCR and IHC methods, we developed a hybrid capture baitset against the entire MCPyV genome and software to detect integration sites and structure. RESULTS: Sequencing from this approach revealed distinct integration junctions in the tumor genome and generated assemblies that strongly support a model of microhomology-initiated hybrid, virus-host, circular DNA intermediate that promotes focal amplification of host and viral DNA. Using the clear delineation between virus-positive and virus-negative tumors from this method, we identified recurrent somatic alterations common across MCC and alterations specific to each class of tumor, associated with differences in overall survival. Finally, comparing the molecular and clinical data from these patients revealed a surprising association of immunosuppression with virus-negative MCC and significantly shortened overall survival. CONCLUSIONS: These results demonstrate the value of high-confidence virus detection for identifying molecular mechanisms of UV and viral oncogenesis in MCC. Furthermore, integrating these data with clinical data revealed features that could impact patient outcome and improve our understanding of MCC risk factors.


Related Papers